Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Del Vecchio M, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V. Vergani E, et al. Among authors: vergani b. Cell Commun Signal. 2020 Sep 23;18(1):156. doi: 10.1186/s12964-020-00601-1. Cell Commun Signal. 2020. PMID: 32967672 Free PMC article.
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Vergani E, et al. Among authors: vergani b. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. Oncotarget. 2016. PMID: 26684239 Free PMC article.
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, De Laurentiis A, Lalli L, Di Guardo L, Patuzzo R, Vergani B, Casiraghi E, Cossa M, Gualeni A, Bollati V, Arienti F, De Braud F, Mariani L, Villa A, Altevogt P, Umansky V, Rodolfo M, Rivoltini L. Huber V, et al. Among authors: vergani e, vergani b. J Clin Invest. 2018 Dec 3;128(12):5505-5516. doi: 10.1172/JCI98060. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260323 Free PMC article.
Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.
Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M. Vallacchi V, et al. Among authors: vergani e, vergani b. Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672. Cancer Res. 2014. PMID: 24395820
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.
Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, Santinami M, Cabras AD, Arienti F, Triebel F, Rodolfo M, Rivoltini L, Castelli C. Camisaschi C, et al. Among authors: vergani e, vergani b. J Invest Dermatol. 2014 Jul;134(7):1893-1902. doi: 10.1038/jid.2014.29. Epub 2014 Jan 17. J Invest Dermatol. 2014. PMID: 24441096 Free article.
Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells.
Tuccitto A, Tazzari M, Beretta V, Rini F, Miranda C, Greco A, Santinami M, Patuzzo R, Vergani B, Villa A, Manenti G, Cleris L, Giardiello D, Alison M, Rivoltini L, Castelli C, Perego M. Tuccitto A, et al. Among authors: vergani b. Stem Cells. 2016 Oct;34(10):2449-2460. doi: 10.1002/stem.2413. Epub 2016 Jun 28. Stem Cells. 2016. PMID: 27301067
63 results